Current Profile of GMOs in India Table 3 Budgetary Allocations of Major Funding Agencies in India Table 4 All India Production of Biofertilisers Table 5 Indian Seed Market Table 6 Venture Capital Disbursements in India (2001) Table 7 Investment, Total Employees and Turnover of Biotechnology Industry in India Table 8 Biotechnology Statistics Collection in India In order, to effectively analyze the various linkages between biotechnology and other sectors, in light of their plan priorities, it is important to build a data set for informed policy making in these countries.
The biotechnology programs in developing countries are to be evolved in such a way so that potential benefits of this technology remain rooted in the national development strategy. In the context of developing countries, one would have to be extremely careful while selecting the indicators, which can address their needs and requirements. 4 The indicators should reflect capability of this technology in terms of dealing with the challenges in different sectors. In the agricultural sector, for instance, managing food security, nutritional security and working for reducing input demand for crops, are some of the important targets to be statistically captured. In China genetically modified rice offers 15 per cent higher yields without the need for increases in other farm inputs and modified cotton (Bt cotton) allows pesticide spraying to be reduced from 30 to 3 times 1 . Similarly in the health sector providing access to lifesaving drugs and cost effective vaccine production are some of the other major challenges. Scientific achievements in this field have been very encouraging and of direct relevance for dealing with specific challenges before developing countries. For instance, the Hepatitis B vaccine was developed in 1989 and down these years more than 300 biopharmaceutical products are in the world market. They have reduced the cost of adoption and diffusion of these products.
The widespread use of high-throughput experimental approaches and completion of the human genome project have enhanced the number of therapeutic targets available to the pharmaceutical industry.
There may be several more desired attributes, developing economies may expect biotechnology products to be equipped with, such as, longer shelf life value of products and reducing environmental pollution etc. However, it is equally important to emphasize provisions for biosafety policies and adequate regulatory mechanisms to enforce it, when the issue of diffusion of biotechnology comes up.
Accordingly, in the broader biotechnology assessment strategy, biosafety related indicator especially trained manpower should also be incorporated. The central issue is, to what extent developing countries are prepared to evolve appropriate strategies to assess the direction of their biotechnology R&D expenditure and subsequent returns on them.
In this regard, developing countries face several policy challenges. The policy makers, here, have to grapple with several sets of issues, which are to be addressed at different levels and needs to be responded to, in a much different way. In fact, the spectrum of issues is very large for them. It may be difficult to respond to all these questions, as a large number of developing countries, do not have a conceptual classification for positioning biotechnology, in the overall developmental framework. In this paper, an effort is being made to look into some of these issues. Section II analyzes the evolving statistical framework in OECD and some non-member countries. Among the developing countries, India has been chosen here for a case study in data collection in biotechnology. A detailed account of statistics collection in India is reported in section III of this paper. The section IV outlines an agenda for developing countries while last section draws the conclusions from the paper.
II International Initiatives
In recent past, a number of initiatives have been launched to statistically analyse developments in biotechnology and growth of biotechnology industry. Several annual reports from Ernst & Young for the United States and the Europe gave detailed account of corporate data related to biotechnology while publications like, 'International Service for the Acquisition of Agri-Biotech Applications (ISAAA) Briefs', provided insights on adoption of agriculture biotechnology across the world.
However, OECD has initiated a systematic exercise for bringing different perspectives together on various aspects of data collection for biotechnology. Similarly, European Commission and Intermediary Biotechnology Service (IBS) of ISNAR have also initiated a limited exercise for data collection, which we discuss herewith.
II.1 European Commission
The Policy Unit of the European Commission's Life Sciences Program has conceived two studies for collecting biotechnology-related statistics for its member and non-member countries. The first study would cover number of students, researchers, trainees, and employees in both private and public sector as well as their mobility. While the second study would cover all the aspects of biotechnology industry such as number of companies and their employees, investment, R & D spending, patent and other data.
The results of these studies are expected to be out by end of 2003. The studies would be launched
The Commission has also established, on pilot basis, BIOSTAT, a database intended to collect biotechnology related economic data. At present, it largely draws its information from European Commission's Life Science programme supported documentation unit, called BIODOC. It has more than 1000 entries. The focus of this is very wide and it covers political, economic, social, legal, and 6 ethical aspects. It contains information on scientific development and breakthroughs, however rarely in form of original articles. Meanwhile, the commission has launched two studies to look into the manpower profile of biotechnology sector and current status of biotechnology industry in Europe.
II.2 Intermediary Biotechnology Service
International IBS has attached a greater emphasis on collection of data on resource indicators in terms of investments made through public sector allocations. Additionally, these surveys also collect information about size, structure, and content of public research along with some details on international collaborations of public sector organizations. The most important expected output of this initiative is to collect new information for the country reports and the synthesis research reports. These outputs in agricultural biotechnology provide a new set of information that may enrich the decisionmaking capability of the policy makers. 
II.3 OECD

III Case Study of Bio-Statistics in India
Adoption of biotechnology in industrial and other activities is a relatively recent phenomenon in India.
The clarity about its governance has yet to take a concrete shape. However, need for a reliable data set for accurate assessment of its adoption is being widely felt 10 . This has become a pressing need in last one year or so, as formal system for regulation of biotechnology is found to be trailing behind the other informal channels for infusion of this technology, especially, in the agricultural sector. In this section, a brief account of general data collection system in India is given. Then we try to see how need for biotechnology related statistics is being addressed mainly in terms of commercialization of GMOs, R&D allocations and industry statistics. It also provides an outline of a possible plan for adoption of statistical indicators for data collection, as is being done in other parts of the world.
III.1 General Framework of Statistics Collection
The Central Statistical Organisation (CSO), under the Ministry of Statistics and Programme Implementation, is the key agency for data collection on industry. It brings out the Annual Survey of Industries (ASI), which is the principal source of industrial statistics in India. It provides statistical information to assess the changes in the growth, composition and structure of organised manufacturing sector. Industrial sector occupies an important position in the Indian economy and has a pivotal role to play in the rapid and balanced economic development. CSO also comes out with Index of Industrial Production (IIP) which is widely used as a short-term indicator, measuring industrial growth, till the actual result of detailed industrial survey becomes available. Actually, IIP is an abstract number, the 9 magnitude of which represents the status of production in the industrial sector for a given period of time. The CSO being the nodal agency for the development of the statistical system in India, it has paid increasing attention at the emerging issues for data collection, such as collection of environment related data. CSO came out with the first publication containing data on various aspects of environment entitled "Compendium of Environment Statistics" in 1997 11 . Subsequently, it has been decided to bring out this publication on an annual basis. The current issue pertaining to the year 2000 is the fourth in the series. This issue has covered biodiversity-related indicators also. It provides detailed account of germplasm collections in India along with the number of inventorisations for exsitu collections.
In India, collection of trade data and its compatibility with production data has emerged as a major challenge before economists. Authors like related details, at broad macro level but has yet to launch any specific effort to collect biotechnology related statistics.
III.2 Biotechnology Statistics in India
Department of Biotechnology (DBT), under Government of India, has taken a very broad definition of biotechnology. According to the several documents of DBT one gets an impression that, "biotechnology is an application of recombinant and non-recombinant technologies in biological resource utilisation for product and process development aimed for commercialization." Thus, classification of biotechnology commodities for data collection purposes becomes very difficult. This is largely because industrial production of some of these commodities is a recent phenomenon.
Another reason probably is that efforts are yet to be made to conceptually separate them for accounting purposes. As a result, these goods get added in the broad categories for different products. As a result, the estimation of the size of market for biotechnology products also varies a great deal (Table 1) . It seems there might be many other considerations behind these projections. Similarly, problems are being confronted in the data management for patent related details. Technology Information Forecasting and Assessment Council (TIFAC), which is managing the data base for
patents has yet to separately classify the biotechnology patents. ---------------------------------------------------------------------------------------------------------------------------------------- 
III.2.1 Patent Data
At, this point, there is a limited provision in India for granting patents on microorganisms 15 . The prevailing perception is that, as of now, India is not obliged to introduce laws for patenting micro- and genes do not have any protection through patents in India, these will get an indirect protection through the new seeds and plants. In the proposed plant variety Act, a stipulation may be considered so that the genes used in such varieties may also get adequate protection.
III.2.2 GMO Field Releases
Indian agriculture has formally entered the transgenic era in March 2002, with the approval of cultivation of Bt cotton. The Genetic Engineering Approval Committee (GEAC) has permitted seed company, Mahyco, to commercially release three genetically modified hybrid cotton varieties. At present India plants nearly 9 million hectares of land under cotton and produces 3 million tonnes of cotton lint annually. India is the third largest producer of cotton in the world contributing 5.2 per cent of the global production.
The next genetically modified crop to be cleared for commercialization is likely to be mustard. Table 2 gives a broad idea about GM plants being tested at different stages of approval process. It also gives details about the companies, which proposes to commercialise these plants along with the characters being inserted in. According to this table, 4 companies and 7 public research institutes are attempting 12 11 crops for transgenic manipulation. Apart from the UNIDO source being quoted for Table 2 , this data has also been presented by DBT in an international conference recently.
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Biosafety Information Network and Advisory Service (BINAS), UNI DO, various years.
III.2.3 Trade Data
Though efforts have been made to analyse the possible impact of biotechnology on exports (Panchamukhi and Kumar 1988) no separate classification is being followed in India for biotechnology commodities. As a result, it is difficult to assess their position in trade. In fact, even otherwise, in India, 13 the coverage of trade and production data systems often does not match at the disagrregate level. The matching is neither easy nor automatic 17 . In the report of the National Statistical Commission (2001), it has been suggested to adopt national classification code to overcome this problem. The 8-digit coding system being adopted by the Task Force constituted by Central Board of Excise and Customs (CBEC) needs to be finalized urgently. There is also a need to adopt national classification code based on Harmonized Commodity Description and Coding System (HS) by all the producer and user organisations engaged in product-level data. The use of national classification would eliminate the multiplicity of the product-level coding system and would also enable a study of the flow of output through various economic systems apart from cross-classification of activity and product data. Though several non-government organisations have suggested that a large number of GM food and feed is being exported to India but there is hardly any account of it. However, recently Ministry of Agriculture has imposed restrictions on imports of GM soybean oil.
III.3 Government R&D Statistics
There (Table 3) . Each of them has growing allocations for this particular technology. However, except DBT, no agency separately announces budget allocation for biotechnology, as the allocations are included into the broader heads for accounting purposes. Therefore, it is difficult to precisely estimate allocations for biotechnology. Nevertheless, an attempt may be made to collect this statistics, as one may go unto the level of laboratories and research institutes to find out nature and composition of biotechnology programmes at that level and this would certainly give a definite indication about the allocations.
In recent past, a couple of analytical papers have been published by individual coordinators of different government programmes, giving details of data related to the programmes they are dealing with (Ghosh 1997 , Wahab 1998 , Ramanaiah 2002 . These papers are full with insights and at places give time series data. Otherwise, at one place, it is difficult to get full account of biotechnology statistics.
However, harmonization of concepts about biotechnology across these agencies may help in resolving this difficulty to some extent.
14 The details available from DBT about the allocations is being presented in Figure 1 . This gives data in absolute numbers and thus, does not take into account monetary devaluation due to inflation, etc.
However, Figure 2 It is not that they were not getting allocations earlier but now with this changed approach these areas have come upfront when allocation are being discussed. Source: RIS based on DBT Reports (several years).
Table 3: Budgetary Allocations of Major Funding Agencies in India ($ Million) ------------------------------------------------------------------------------------------------------------------------------------1990/91 2000/01 ------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------
III.4 Statistics collected by Private Organisations
There are couple of major private sector organisations, which have been coming out with biotechnology statistics for India. However, leaving one or two aside they are largely focussed to a particular sector only. For instance, All India Biotech Association (AIBA) has been regularly coming out with details about adoption and production of biofertilizers and biopesticides while PharmaBiz (a private web site) has been providing details about medical biotechnology only. Confederation of Indian Industries (CII) and Ernst and Young are the agencies, which may provide a macro picture of biotechnology industry. However, they also have yet to launch an exercise for regular data collection.
The Fertiliser Association of India (FAI) regularly brings out production and composition statistics about biofertilisers in India. Table 4 gives some details about total quantum of biofertiliser being putting data together has facilitated evolution of macro level perception of various agricultural input industries. Sadananda (2002) has made an effort to analyse Indian seed industry (Table 5 ).
Table 4: All India Production of Biofertilisers ----------------------------------------------------------------------------------------------------Year Biofertiliser
No. of Producing firms ('000 tonnes) -------------------------------------------------------------------------------------------------- 
Biofertiliser Statistics, various issues, FAI, New Delhi The venture capital has emerged as a major source of funding frontier technologies across the world.
Biotechnology has attracted a large number of commitments by different agencies. This report has presented a broad picture of these allocations on the basis of press clipping and other sources. This is being presented in Figure 3 . However, some agencies like National Association of Software and Services Companies (NASSCOM) also occasionally come out with some statistics on venture capital disbursement in India. One of the recent report from NASSCOM gives detailed information about the number of companies which received venture capital across major Asian economies. This has been briefly presented in Table 6 . 
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III.5 OECD Methodology and Current Data Collection Exercise in India
As is clear from Table 8 limited efforts have been made by different agencies to collect statistics on biotechnology. The DBT Annual Report gives detailed account of budgetary allocations including for R&D and other heads. The data collection exercise is to be further strengthened in the sense that there are many other agencies allocating budgets for biotechnology related projects. Moreover, a consensus on the definition of biotechnology per se is yet to be attempted. Therefore, nature of technology being supported under the head of biotechnology probably may lead to different sets of conclusions altogether. According to OECD, following approach has been adopted to define biotechnology.
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The Single definition
The single definition agreed to, by the OECD ad hoc committee meeting was as follows:
"The application of science and technology to living organisms, as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge, goods and services."
The List based defintion
The list based definition agreed to by the ad hoc meeting contains the following five categories:
1. DNA (the coding) genetics, pharmaco-genetics, gene probes, DNA sequencing/synthesis/simplification, genetics engineering.
Proteins and molecules (the functional blocks):
Protein/peptide, sequencing/synthesis, lipid/protein engineering, proteonics, hormones, and growth factors, cell receptors/signalling/pheromonics.
Cell and tissue culture and engineering:
Cell/tissue culture, tissue engineering, hybridisation, cellular fusion, vaccine/immune stimulants, embroyo manipulation.
Process biotechnologies:
Bioreactors, fermention, bioprocessing, bioleaching, bio-pulping, bio-bleaching, biodesulphurization, bioremediation and biofiltration.
Sub-cellular organisms:
Gene therapy, viral vectors.
The data being collected in India by organisations such as BCIL, FAI and AIBA largely depend upon feed back from questionnaire being sent to different companies. However, they make efforts to supplement information through secondary sources such as reference books, internet, company profiles and reports. The general sensitivity about precise definition of biotechnology and about its various other sub-components, while data is being collected seems to be very low. Moreover, the frequency is not very regular. Therefore, strong efforts have to be made to initiate a dialogue among at least few of these agencies to adopt a common definition and clearly define methodology for data collection.
National Science and Technology Management Information System (NSTMIS) at Department of Science and Technology (DST) is planning to initiate some exercise in this regard. NSTMIS has already initiated a project to map biotechnology capability in its entirety through an assessment of 22 various types of competence, embodied knowledge and research infrastructure. This will be achieved through the use of direct questionnaires, interviews and assessment of projects and patents. This will involve mapping the technology capability in terms of R&D expenditure and manpower in the various segments such as research, manufacturing, consulting and biotechnology products developed, projects in vogue, services provided, patents granted, research, testing and production infrastructure. This study will cover major biotechnology firms, research institutions, consultancy services as well as biotechnology research at major universities. is yet to be launched. _______________________________________________________________________ Source: Chaturvedi, Sachin (2002b) .
IV Agenda before Developing Countries
At the international level, there is an over dominating emphasis on data collection on biotechnology process and product development along with statistics collection on social attitudes towards biotechnology. In the context of developing countries, the concerns and perceptions about biotechnology and its diffusion are much different than say in the developed countries. The basic policy concerns in developing countries are much wider and deeper. As has been mentioned earlier, they range from resource substitution for R&D among different technologies to sustenance of food security, ensuring availability of low cost but effective vaccines etc. They also have country specific challenges in terms of human resource development and also in terms of establishing right kind of linkages among different constituents of a national innovation system. Accordingly, the formulation of indicators should be such that they capture contribution of biotechnology towards these ends.
Since in developing countries, share of public allocation for R&D is many times more than the private sector allocation in biotechnology, it is important for the policy planners to correlate R&D priorities in new technologies with the technological constraints emerging from conventional methods. At this point, biotechnology is being attempted in many developing countries in isolation of their established R&D systems 18 . As a result, its infusion and absorption has largely remained at the periphery only. The technological frontier for developing countries has to be an outcome of accumulation of both new and conventional techniques rather then an outright replacement of the conventional techniques with new techniques 19 . For instance, most of the green revolution varieties of different crops have reached their peaks in terms of their productivity 20 . Similarly, in the health sector tropical diseases still get very little attention of international agencies. Therefore this aspect should be addressed on priority basis in the health sector research agenda. Therefore expenditure on biotechnology R&D would be justified if budgetary allocations move research agenda in the direction which can solve these problems.
Apart from influencing R&D planning towards these objectives it is also important to ensure that adequate infrastructure comes up to support indigenous research endeavors. This includes both physical infrastructures like high-grade instruments and advanced laboratories, adequate germ-plasm collection, etc. and human resources. There again, the human resource development is to be encouraged at various levels and in different magnitudes. Since biotechnology program objectives needs to be very clear, the developing countries might even have to plan for manpower with superspecialization to attend the high priority areas defined by the relevant public policy. An attempt is 24 being made in Table 9 to capture these different attributes in one matrix to determine the position and direction of biotechnology policy in different countries. This is specifically attempted for agricultural sector but may be extended to others with change in biotechnology attributes and policy targets 21 . The factors determining economic cost would largely remain the same. The matrix consists of the major crops in a given developing country on the vertical axis, while the aggregate cost values for R&D, IPR protection, biosafety enforcement, infrastructure, distribution cost and cost for human resource development all on the horizontal axis. These costs may be involved in introducing any of the biotechnological traits such as pest resistance, drought resistance and productivity improvement etc. in the ordinary varieties of different crops listed on the vertical axis. These crops are generally important for food and nutritional securities or exports of developing countries. regulations related to GMOs to the SPS Committee, most of the discussion on the subject has been in the TBT Committee with the focus on labelling regulations. However, since quarantine agencies in developing countries are not well equipped to identify biotechnology goods, it is important to ensure a separate category for biotechnology goods under HS and SITC trade classifications. This would have to be addressed on a priority basis as far as international biotechnology statistics is concerned. While at the domestic level indicators related to national innovation system are important and relevant for policy formulations.
V Concluding Remarks
As is clear, biotechnology has reached at a stage of development and diffusion where developing countries should take stock of its direction and related cost of its adoption. This exercise would also Biotechnology, especially in the agricultural sector at WTO, is facing a major challenge in terms of intellectual property rights regime. This is a new instrument in the agricultural sector. The data being collected on patents and their classification has yet to reflect on some of the concerns mentioned earlier. The patenting of research tools in biotechnology has generated a wide debate. A database on biotechnology patents would help in bringing out these trends in a comprehensive manner. WIPO has made an effort to address to these concerns through some of its projects but as is clear more has to be done.
